Cell No. : Cell Name
RCB0659 : HOUA-I
update : 2022/07/07
|
| Comment | Human cell line derived from uterine cancer (endometrial cancer). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Ishiwata, Isamu
|
| Originator |
Ishiwata, Isamu
|
| Year of deposit |
1991
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Female
|
| Age at sampling |
55 years
|
| Tissue |
endometrium
|
| Disease name |
Endometrial adenocarcinoma
|
| Classification |
cancer
|
| Year of origin |
1982
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_3867
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
HamF12 + 15% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : once/3-4 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Virus (HIV) |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
43-92(50) : /44(1),45(10),46(19),47(3),48(3),49(1)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
5
|
| User's Publication |
10
|
| Reference |
|
41
Ishiwata I, Ishiwata C, Nozawa S, Ishikawa H.
CA125 production by gynecologic tumors in vitro and its modulation induced by dibutyl cyclic adenosine monophosphate
Asia Oceania J Obstet Gynaecol
1996
12(2):285-90
PubMed ID: 2429643
DOI: 10.1111/j.1447-0756.1986.tb00192.x
|
|
46
Nakai T, Endo K, Hosono M, Saga T, Watanabe Y, Sakahara H, Imai K, Yachi A, Kiyozuka Y, Ishiwata I.
Drug effects on CA125 antigen expression and antibody binding to cancer cells
Int J Cancer
1991
48(3):463-7
PubMed ID: 1645702
DOI: 10.1002/ijc.2910480326
|
|
45
Saga T, Ishiwata I, Endo K, Sakahara H, Koizumi M, Watanabe Y, Nakai T, Hosono M, Ishikawa H, Sawada M.
An antibody-tumor model for the targeting of CA125-producing gynecologic malignancies
Jpn J Cancer Res
1990
81(11):1141-8
PubMed ID: 2125039
DOI: 10.1111/j.1349-7006.1990.tb02526.x
|
|
1522
Ishieata, I., Soma, M., Ono, I., Nakaguchi, T., Ishiwata, C., Nozawa, S.and Ishikawa, H.
Biological Characterristics of Adenocarcinoma Cell Line ( HOUA-I ) and B-Lymphoblastoid Cell Line ( HOUA-II ) Established from The Same Tissue of Endmetrial Adenocarcinoma
Jikeikai Medical Journal
1989
36:303-315
|
|
1035
Ishiwata I, Ishiwata C, Soma M, Ono I, Nakaguchi T, Ishikawa H.
Tumor angiogenic activity of gynecologic tumor cell lines on the chorioallantoic membrane
Gynecol Oncol
1988
29(1):87-93
PubMed ID: 2448191
DOI: 10.1016/0090-8258(88)90151-5
|
| User's Publication |
|
19737
Yagi H, Onoyama I, Asanoma K, Kawakami M, Maenohara S, Kodama K, Matsumura Y, Hamada N, Hori E, Hachisuga K, Yasunaga M, Ohgami T, Okugawa K, Yahata H, Kato K.
Tumor-derived ARHGAP35 mutations enhance the Gα13-Rho signaling axis in human endometrial cancer
Cancer Gene Ther
2023
30(2):313-323
PubMed ID: 36257976
DOI: 10.1038/s41417-022-00547-1
|
|
13927
Xu D, Dong P, Xiong Y, Chen R, Konno Y, Ihira K, Yue J, Watari H.
PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3
Front Cell Dev Biol
2020
8:598205
PubMed ID: 33363153
DOI: 10.3389/fcell.2020.598205
|
|
14241
Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, Kudo M, Sakuragi N.
EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis
Oncotarget
2017
8(8):13509-13520
PubMed ID: 28088786
DOI: 10.18632/oncotarget.14586
|
|
17129
Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N.
MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines
Mol Carcinog
2014
53(5):349-59
PubMed ID: 24002805
DOI: 10.1002/mc.21983
|
|
7708
Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, Sakuragi N.
MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.
Mol. Cancer
2011
10:99
PubMed ID: 21851624
DOI: 10.1186/1476-4598-10-99
|
|
8772
Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.
Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.
Kobe J Med Sci
2007
53:177-87
PubMed ID: 18204294
|
|
13795
Sugawara T, Nomura E, Fujimoto S.
Expression of enzyme associated with steroid hormone synthesis and local production of steroid hormone in endometrial carcinoma cells
J Endocrinol
2004
180(1):135-44
PubMed ID: 14709152
DOI: 10.1677/joe.0.1800135
|
|
13831
Unoki M, Nakamura Y.
Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity
FEBS Lett
2003
554(1-2):67-72
PubMed ID: 14596916
DOI: 10.1016/s0014-5793(03)01092-5
|
|
3101
Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, Nishida M, Satoh T, Tanaka T, Nakamura Y
Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN.
Cancer Res
2001
61:3741-9
PubMed ID: 11325847
|
|
1902
Shu Qin Liu, Kaoru Saijo, Makoto Kodama, Tadao Ohno
Intelligent matrices for tumor-specific cytotoxic T lymphocytes
Materials Science and Engineering: C
1994
2:61-65
DOI: 10.1016/0928-4931(94)90030-2
|
Back
Top
CELL BANK Website
